Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2019 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (111)	2/15/2019 9:04:47 PM
From: BulbaMan	Read Replies (2) \| Respond to of 280

2/15/2019 Contest update The evidence for collusion is incontestable. Given that today is the third Friday of the month, I imagine you’ve guessed I’m referring to the phenomenon of stock prices, including of biotechs, being pinned to option strike prices on option expiration days. For example, see this: math.nyu.edu Meanwhile, biotechs had a stellar week. At Friday’s close, the Contest median was up 16.30% YTD (vs. 12.26% YTD a week ago), the Nasdaq Biotech Index (NBI) was up 15.67% YTD (vs. 11.41% YTD a week ago), the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was up 20.26% YTD (vs. 14.85% YTD a week ago) and the Nasdaq Composite Index (NCI) was up 12.62% YTD (vs. up 9.99% YTD a week ago). CNST, the top stock gainer for the second week in a row, catapulted Contest leader HOOD’s portfolio to a spectacular 51.93% YTD gain. SANCTU’s portfolio, up 35.49% YTD and DEWDIL’s portfolio, up 31.82% YTD, remained in second and third place. At Friday's close, all 39 Contest portfolios were in the green, with 21 beating the NBI and 13 beating the super hot SPSIBI. The 167 Contest stock picks have an average YTD gain of 19.73% and a median YTD gain of 17.71%. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.) Portfolio adjustments: 1) CLDX did a 1-15 reverse split. 2) Axovant (AXON) changed its name and symbol to Arvelle Therapeutics (AXGT). Yahoo Quotes hadn’t yet made the change as of this update. I’ll make the adjustment once Yahoo makes the change, I assume by next Friday. 3) The LOXO buyout at $235 by Eli Lilly closed and I reallocated the proceeds using the 2/15/19 closing prices. Only a single Contest portfolio held LOXO, JACKH. (All corrections, especially adjustments for splits & mergers, greatly appreciated.) Enjoy a relaxing President’s Day weekend biotechies! Peace & good health, Bulba 2/15/19 Rank Name Profit/Loss 1 HOOD 51,931 2 SANCTU 35,489 3 DEWDIL 31,819 4 JACKH 30,374 5 RKRW 29,691 6 BIOADD 25,519 7 GHMM 22,100 8 ANDRE 22,006 9 FILO 21,612 10 DOUGH 21,572 Week's Top 5 Gainers Symbol 2/8/19 2/15/19 Wk.%chg. CNST 9.350 11.930 27.59% MGTA 7.490 9.240 23.36% AGRX 0.890 1.070 20.22% HEMA 11.320 13.400 18.37% CRBP 7.680 8.950 16.54% Week's Worst 5 Losers Symbol 2/8/19 2/15/19 Wk.%chg. XERS 14.900 9.730 -34.70% DMAC 4.000 3.170 -20.75% PTE 16.830 14.340 -14.80% ASLN 3.650 3.210 -12.05% CMRX 2.200 1.990 -9.55%